I have contacted her 4 times over the last couple of days without her responding.
We ALL need to flood her with requests to let the company know that the OWNERS are not happy.
Take the time to let her know and ask that she relay this to management.
It can't hurt and maybe even HELP.
As I posted in another string yesterday, it is very important for the company to attract the clinical investigators to study Imetelstat in their areas of interest from a pure science point of view, NOT to appear overtly commercial at this point. Commercialism makes investigators hesitant to become involved for fears of a taint of scientific dishonesty.
As end2war has said, we have a nice monthly upward trend going here in pps. Let's not be too much like the day traders or MMs. IMHO
77 and irish: good jobs!!!!
77: the problem with Anna's response it that it is far too general and non-specific. Investors want some beef. What we got was some do-do and then some more do-do. But, that's par for GERN so why should we expect more?
Of course, IMO.
This is my email to investor relations at Geron
Anna and Executive Management,
As a long time investor I am far from satisfied with the companies performance over the last 6 years. Now with positive data Geron is in a good place to have a life saving, industry changing, and income producing cancer treatment. WHAT IS THE GAME PLAN? No executive bonuses, no fancy holiday parties I want my investment return if there is a chance. Myself along with thousands of other investors are sitting tight waiting for the company to provide their strategy for the success of Geron. Remember the "shareholder wealth" concept from economics 101? That should be the number one priority. Please let us know what if any plans Geron has for my hard earned money so that I can make educated and accurate investment decisions.
Sentiment: Strong Buy
This is her response:
Thank you for your email and comments.
We have previously stated our intention to initiate a multi-center, company-sponsored clinical trial of imetelstat in patients with myelofibrosis in the first half of 2014. We have also stated that we expect to give guidance in the first quarter of 2014 regarding the scope, design and timing of that next clinical trial, as well as on the development and registration plan for imetelstat in myelofibrosis.
In the meantime, we are very appreciative of your long-term support and patience.
This is my email: when do you plan on issuing a press release about the excellent results of Imelestat, if ever? Is there a reason you are keeping this information a secret while your stock price plummets? Also, patients are dying and might want to determine if/when they might enter a trial or expect the drug to become available to them. I understand you have multi center trials planned. How are you funding? Inquiring minds wan to know. So? Merry Christmas.
Sentiment: Strong Buy